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Abstract 
Drug resistance in mycobacterium Tuberculosis (MTB) undermines 
the efficacy of Tuberculosis treatment in individuals and of Tuberculosis 
control programmes in populations. Non compliance of anti Tuberculosis 
drugs can result in drug resistance MTB strain. Some fluctuation tests 
demonstrate that mutation to resistance is 2.56 X 10-8  and 2.25 X 10-10  per 
bacterium per generation respectively for isonized and rifampicin. Here, we 
propose a model for the growth of initial drug sensitive bacilli  population 
taking into consideration conferred mutations. This was validated against 
experimental data. The model shows that if the total number of the MTB 
strain is less than 39,062,500 and 4,444,444,444 with selective effect to 
isoniazid and rifampicin respectively, the explosion can  eventually be 
contained. This is far less than clinical bacterial load of 1010. This finding 
may also help explain the pharmacodynamic properties of the "first line" anti 
Tuberculosis drugs. 
 
Keywords: Branching process modeling, disease transmission, drug 
susceptibility, stochastic process 
 
1.0 Introduction 
Tuberculosis has been found in the mummies of ancient Egyptians 
and Andean Indians demonstrating that it has been in humans for thousands 
of years. It was first identified by Dr. Robert Koch in 1882. The disease was 
historically referred to as “consumption.” The scientific name for the 
Tuberculosis microbe is Mycobacterium tuberculosis or MTB. Beneath a 
microscope, it has a long rod-like shape and thick, waxy-looking coat. The 
Bacteria are single-celled organisms which can exist either as independent or 
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as parasites. The thick waxy cell wall allows the germ to spread through the 
air and survive on surfaces for weeks.  
Unlike most bacteria which divide within minutes or hours, TB 
bacterium splits into two only once every 16-20 hours. This asexual process 
is known as binary fission. MTB has all the necessary genetic material to 
reproduce so it does not require a host. 
 According to the United States global health policy fact sheet in 
2010, One-third of the world’s population, or two billion people, carry the 
TB bacteria, more than 9 million of whom become sick each year with 
“active” TB which can be spread to others. “Latent TB” disease cannot be 
spread.TB disproportionately affects people in resource-poor settings, 
particularly those in Asia and Africa (WHO, 2009, 2010).TB cases and 
deaths occur in developing countries, constituting significant challenges to 
the livelihoods of individuals primarily during their most productive years 
with more than 90% of the new cases in developing countries (WHO, 2009). 
When active TB is manifested, the infection is normally treated with 
antibiotics, thereby providing an external pressure for the selection of 
antibiotic resistant bacilli. The risk of resistance development is determined 
by a number of different factors, including the antibiotic selective pressure 
(set by the number, dosing and quality of the used drugs), any pre-existing 
resistances in the infecting clone, the immune status of the treated 
individuals and their compliance with the drug ( Mariam et al., 2011). 
There have been some challenges in the past decades in the fight 
against TB. We categorized the challenges into two: First, treatment 
challenges in terms of how to deal with drug-to-drug interactions, over dose 
regimen to children and infants due to little or no data on best treatment. 
Secondly, challenges in terms of drug resistance which researchers have still 
not made great achievements on how best to treat drug resistant TB. Many 
high-burden settings lack the facilities to detect drug resistant TB as well as 
difficulty in understanding all of the mutations that correspond with 
resistance.  
According to The World Health Organisation (WHO) almost 500,000 
people develop multidrug-resistant TB (MDR-TB) every year (WHO, 2009). 
This form of TB is highly resistant to conventional front-line drugs and 
places additional force on public health care systems. Globally in 2012, an 
estimated 450,000 people developed MDR-TB and there were an estimated 
170,000 deaths from MDR-TB (WHO, 2013). MDR-TB is defined as disease 
resulting from MTB infection by strains that are resistant to frontline TB 
drugs, isoniazid (INH) and rifampicin (RIF) (Gagneux, 2006). Treatment for 
drug sensitive (DS) TB is less than optimal, partly because the onerous 6 
month treatment period leads to noncompliance, especially as patients start 
feeling better. MDR-TB treatment regimens are even longer, and the drugs 
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used are more expensive and have extensive side-effects with fewer than one 
in five MDR-TB patients being correctly diagnosed with MDR-TB (Mel, 
2012).Interruption of treatment is one of the factors which allow for the 
development and maintenance of drug-resistant (DR) MTB strains; however, 
biological factors are likely to play a significant role as well (Warner & 
Mizrahi, 2006).  
Our objective in this paper is to provide a model that will enable the 
understanding of the initial evolutionary process of MDR TB strains under 
selective pressure, as well as provide the basis for comparing and validating 
experimental data for better understanding. 
 
2.0 Related Studies 
There has been extensive research on the mathematical modelling of 
TB. For convenience of related literature, we classify them into two phases: 
first, modelling the transmission dynamics of TB among and within human 
populations, and secondly, studies involving the dynamics of MTB 
pathogens.  
Iwasa et al., (2003,2004) used a multi-type branching process to 
model the order of movement of mutants that leads to a drug resistant 
mutant. Their model described different mutation networks in the appearance 
of a drug resistant mutant and calculated the probability of drug resistance. 
Ribeiro and Bonhoeffer (2000) compared two possible scenarios for 
the outgrowth of drug resistant pathogens: either a drug resistant strain exists 
before the treatment or it appears after the treatment starts. They also used 
stochastic simulations to compare the two possibilities. 
Colijn et al., (2011) used a stochastic birth-death model to estimate 
the probability of the emergence of multidrug resistance during the growth of 
a population of initially drug sensitive TB bacilli within an infected host. 
They found that the probability of the emergence of resistance to the two 
principal anti-TB drugs prior to therapy ranges from 5 410 10− −− . Their model 
is analogous to Luria and Delbruck (1943), Lee and Coulson (1949) and 
Zheng (1999).   
Schinazi (2006) presented a discrete time stochastic process to 
evaluate the risk of a treatment induced drug resistance. He assumed that in 
the absence of treatment, a drug resistant pathogen is outcompeted by the 
drug sensitive pathogen and it rapidly dies out if it appears. However, in the 
presence of a drug, the drug sensitive strain is weakened.  
Blower et al., (1996) studied the development of drug resistance 
focusing on threshold Ro. Their study found that control programs could 
become perverse, though this requires a rather high probability of acquisition 
of drug resistance due to treatment. Dye et al., (1998) presented a model for 
drug resistant TB alone. They estimated Ro using Monte Carlo for drug 
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resistant TB. In their study, it was shown that evidence of short course 
chemotherapy can bring resistance strain under control and preventing drug 
resistant TB from emerging which can be achieved by meeting the World 
Health Organisation (WHO)'s targets for case detection and cure.  
Gillespie (2002) asserted that risk of mutants emerging in TB patients 
depends partly on combined mutation rate of 10-25/bacterium/generation. He 
generated the formular for computing the risk of mutation which was found 
out to be an oversimplification if the MTB are found in different 
compartments. 
The motivation we derived from some of these literature is that, most 
of these modelling discussed the transition of MTB, risk of resistance and 
general behaviour of the MTB strain. This study seeks to model the 
containment of MTB strain using stochastic branching process, Though 
analagous to other studies, we focused on the containment of the MTB strain 
as they evolve with risk of resistance to first line anti TB drugs. We validate 
the model with experimental results from some fluctuation analysis. 
 
3.0 The Model 
We first of all present our branding process model to characterize the 
propagation of the  MDR TB strain  . 
We use M to denote the total number of MTB strain and k to denote 
the number of drug resistant MTB strain. The probability of finding a 
successful drug resistant MTB strain  is  /p k M=  
For first line anti TB drugs, the mutation rates to resistance to the 
drugs is 2.56 X 10-8 and 2.25 X 10-10 mutations per bacterium per generation 
respectively for (Isoniazide) INH and RIF (Rifampicin). (Canetti et al., 
1969) and (Hsie & Bryson, 1950). 
Since our objective is to model the selective effect of first line anti 
TB drugs on the MTB colony, our p measures how wide spread the 
resistance MTB strain is. In short, p  is the density of the MDR MTB strain.  
For the early phase of the propagation ,we assume that total number 
of MTB colony is not more than " M ". therefore, we put an upper bound 
of M on the number of times  the MTB strain can multiply. We characterize 
what values can M  take to achieve an extinction probability of 1. 
 
3.1 Branching Process 
The Galton Watson branching process models a population in which 
each individual in generation n  independently produces some random 
number of individuals in generation 1n +  according to a probability  
distribution that does not vary from individual to individual (Karlin et 
al.,1975). 
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All MTB strain can be classified into generations in the following 
manner. The initial MTB strain belongs  to the 0th generation. all MTB strain 
that are directly  given birth to by the initial  parent are the 1st generation 
regardless of when they are given birth to. In general, an MTB strain bk  is an 
( 1)thn +  generation if it is given birth to directly by an MTB strain ak  from  
the thn generation. bk is also called an offspring of ak . All MTB strain forms 
a tree if we draw a link  between a parent and its offspring. 
Let X be a random variable with offspring distribution 
( )0 1 2, , ,......, kp p p p , during the initial phase of the evolution of the  MTB 
strain, X is a binomial random variable ( ),M p  
( ) ( )M k m kkP X k p q −= =                                                                            [1] 
1q p= −  and  p  is the density of the MTB strain. p remains constant since 
the number of MDR TB strain is smaller than the drug sensitive TB strain. 
Further,we let nZ  be the number of  MTB strain in the  
thn generation. 0Z is the number of initial MTB strain. 
In the early phase of the evolution of the MTB strain, each MTB 
strain  in the thn generation produces a random number of  MTB  strain 
according to the same probability distribution. These newly produced MTB 
strains are ( 1)thn +  generation. 
let ( )nkX  denote the number of drug sensitive MTB strain that have 
become resistant by the thk  MDR MTB strain in the thn generation. The 
number of MDR MTB strain in the ( 1)thn +  generation can be  expressed as: 
( )
1
1
nz
n
n k
k
Z X+
=
=∑ ,where ( )nkX are independent binomial (M ,p) random variables. 
During the initial MDR MTB strain evolution, each MDR MTB 
further produces offspring independently and according to the probability 
distribution in [1].  Therefore the spread of the MDR MTB strain  in each 
generation ( ), 0nZ n ≥  forms a branching process. 
 
3.1.1 Branching  process and probability generating functions. 
A discrete random variable X with probability mass function p(x) has 
a probability generating function (PGF)  
( ) ( ) ( )
0
X x
X
x
G s E s p x s
∞
=
= =∑                                                                     [2] 
If Zn is the number of individuals at time n (Z0=1 ), and Xi is the 
number of offspring of individual of i. 
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12 1 2
....... ZZ X X X= + + +  
So, 
( ) ( )2 1 1[ ]G s G G s=  
and for the nth generation, Let Yi= the number of offspring of ith member of 
(n-1)th generation. 
1 2 1.......n ZnZ Y Y Y −= + + +  
and so  
( ) ( )1 [ ]n nG s G G s−=  
( ) ( )2[ [ ] ]n nG s G G G s−=  
( )
( ) ( )[ [.....[ ].....]
n
n
G s
G s G G G s
=
=

                                                              [3] 
 Moments can be calculated from [2] as:  
( ) ( ) ( )
( ) ( )
( ) ( )
0
1
1
x X
x
X
G s p x s E s
Then
G s E Xs
G E X
∞
=
−
= =
′ =
′ =
∑
 
 Likewise 
( ) ( )( )
( ) ( )( ) ( ) ( )
2
2
1
1 1
XG s E X X s
G E X X E X E X
−′′ = −
′′ = − = −
 
So  
( ) ( ) ( )2 2Var X E X E X= −  
  
( ) ( ) ( ) ( )
( ) ( ) ( ) ( )
2
2
1
1 1 1
Var X G s E X G
Var X G G G
′′ ′= + −  
′′ ′ ′= + −
 
Generally, 
  
( )
( )2 2
1 , [4]
1 [5]
G
G
µ
σ µ µ
′=
′′= + −
 
 
3.1.2 Mean size of nth generation of the branching process. 
Let ( ) ( )n nE x and let E Zµ µ= = . We know that ( )1Gµ ′= . From [3] 
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( )
( ) ( )
( ) ( ) ( )
( ) ( ) ( )
( ) ( )
1
1
1
1
2
1 2
( ) 1
[ ]
[ ]
1 [ 1 ] 1
1 1
......
n n
n n
n
n
n
n n
E X G
G s G G s
G s G G s G s
G G G G
G G
So µ µ µ µ µ µ
−
−
−
−
− −
′=
=
′ ′ ′⇒ =
′ ′ ′=
′ ′=
= = = =
 
It can be seen that as n →∞  
1
1 1
0 1
n
n
µ
µ µ µ
µ
∞
= → =




 
 So at first sight it looks as if the generation size will either increase 
unboundedly ( 1µ  ) or die out ( 1µ  ). 
 
3.1.3  Extinction Probability For The MDR TB Strain.   
For mathematical  convenience, we assume that the initial number of 
MDR MTB strain is 1.  
Let EXµ = be the mean number of offspring per MDR MTB strain. 
Let γ  denote  the probability that the population of MDR MTB strain dies 
out  eventually. 
( ) ( )0nP MDR MTB strain dies out P Z for some nγ = = =  
 In the case of our study, the extinction probability measures the 
likelihood of the MDR MTB strain dying out after a number of generations. 
 When 1γ = , we are certain that the population of the MDR MTB 
strain cannot be exploded for an arbitrarily number of generations. 
 The proposition below provides a sufficient and necessary condition 
for the extinction. 
Proposition: 
Let  p  be the density of the MDR MTB strain and the total number of 
drug sensitive MTB be M. Then 1γ =  if and only if 1M
P
≤  
Proof: Recall that the growth of the MDR MTB strain forms a 
branching process where each MDR MTB strain independently produces a 
random number of offspring. 
Let X  represent the random variable of the  number of offspring 
produced by each MTB strain. Since the total number of MTB strain is M , 
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then X is a binomial random variable with distribution as in [1] with mean 
( )E X Mp= . 
1γ =  if and only if ( ) 1E X ≤  ( Ross, 1996) 
 Therefore 1γ =  if and only if 1M
P
≤ . 
 The practical implication is that if we limit the bacteria colony to less 
than 1
P
, the evolutionary process of the MDR MTB strain can eventually be 
contained. 
 We use this to provide  the basis for assessing fluctuation test 
regarding the frequency of mutations of the MTB strain. 
Table 1. Analysis of Fluctuation Test. 
Firts Line Anti TB 
Drugs 
Mutation Rate Per 
Bacteria/Generation 
1/P Clinical Bacteria 
Load 
INH 2.56 X 10-8 39,062,500 108-1010 
RIF 2.25 X 10-10 4,444,444,444 108-1010 
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Figures 1 and 2 illustrate our claim that the explosion of the MTB strain can be contained 
with conferred resistance to INH and RIF. Figures 3 and 4 demonstrate the difference 
between INH and RIF's resistance as the DS strain explodes. 
 
4.0 Results and Discussion 
Drug resistant M. tuberculosis arise in clinical practice when therapy 
is inadequate.This could be the result of inadequate prescription or because 
the patient fails to adhere fully to an appropriate treatment regimen. The 
basis for the molecular understanding of this resistance has been established 
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(Musser, 1995). In this study, we have used a branching process model for 
the growth of an initial drug sensitive bacilli population taken into 
consideration conferred mutations. 
The beauty of this model is that it can form the basis for comparing 
several fluctuation analysis. Different authors have come out with different 
mutation rates for the MTB strain under different susceptibility testing to 
understand the dynamics of MTB strain in the context of in vitro infection. 
Shimao (1997) and Gillespie (2002) indicated a population size of 8 1010 10−  
bacilli organisms as the bacterial load. Fluctuation test demonstrated that 
resistance to specific anti TB drugs arises spontaneously at a rate of 
6 910 10− cell divisions depending on the drug. 
Mutation from DS to DR for both INH and RIF declined sharply with 
increasing DS load for our containment model in Figs 1 and 2. In Fig 3, the 
mutation rate continued to increase at a constant rate after the 90th generation 
as the DS strain exploded to the clinical bacterial load. Surprisingly, In Fig 4, 
mutation for RIF declined sharply after the 10th generation and maintained a 
constant rate as the DS strain hit the clinical bacterial load.Could this be due 
to the fact that clinical response to chemotherapy  for RIF was considerably 
poorer in patients with initial RIF resistance?. 
Using INH and RIF which are the common first line anti TB drugs, 
proposition 1 implies that if the total number of MTB strain is less than 
39,062,500 and 4,444,444,444 respectively for INH and RIF, the explosion 
can eventually be contained. This is far less than the clinical bacterial load of 
8 1010 10− . 
  
 5.0 Conclusion 
Clinically, the symptomatic population size of 1010 can be kept under 
control, hence, further critical concentration  levels of the anti TB drugs can 
be studied to improve the treatment process as well as reduce the frequency 
of mutations. 
Appropriate dosages of INH and RIF can be determined to continue 
treatment for the DS MTB strain as our containment model suggest a 
reduction in the mutation frequency with increasing DS population given the 
assumption of compensatory fitness cost for the DR strains 
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Appendix1: R codes 
x=0:100 
> p=dbinom(0:100,39062500, 2.56*10^-8) 
> q=dbinom(0:100, 4444444444, 2.25*10^-10) 
> par(mfrow=c( 2,2)) 
>plot(0:100,dbinom(0:100,39062500,2.56*10^8),,type='l',col="red",xlab="Contain
ment load of 39062500",ylab="probability",main="Prob Dist of INH 
Resistance",sub="Fig 1. No. of Drug Sensitive MTB strain") 
>plot(0:100,dbinom(0:100,4444444444,2.25*10^10),,type='l',col="red",xlab="Cont
ainment load of 4444444444",ylab="probability",main="Prob Dist of RIF 
Resistance",sub="Fig 2. No. of Drug Sensitive MTB strain") 
>plot(0:100,dbinom(0:100,10^10,2.56*10^8),,type='l',col="blue",xlab="clinical 
bacterial load of 10^10",ylab="probability",main="Prob Dist of INH 
Resistance",sub="Fig 3. No. of Drug Sensitive MTB Strain") 
>plot(0:100,dbinom(0:100,10^10,2.25*10^10),,type='l',col="blue",xlab="clinical 
bacterial load of 10^10",ylab="probability" ,main="Prob Dist of RIF Resistance", 
sub="Fig 4. No. of Drug Sensitive MTB Strain") 
 
 
 
 
 
